FLT3 and acute myeloid leukemia: After pharmaceutical benefits scheme approval of midostaurin for fms‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach to AML induction with 7+3 chemotherapy (7 days of infusional cytarabine with three doses of anthracycline) to align with future clinical trial protocols.